GSK at a glance

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together.

We prioritise innovation in vaccines and specialty medicines to prevent and treat disease.

A leading biopharma company

  • People worldwide

    70k
  • Countries we operate in

    80+
  • Manufacturing sites

    37
  • Countries that receive GSK products

    112

Innovation

  • R&D investment in 2022

    £5.5bn
  • People working in R&D

    15k
  • R&D centres

    4
  • New collaborations and acquisitions in 2022

    7

Performance

  • Vaccine doses and medicine packs delivered in 2022

    2.3bn
  • Vaccine and medicine sales in 2022

    £29.3bn
  • Products exceeding £1bn sales

    10

Trust

  • In the Access to Medicine Index

    1st
  • In our industry for the S&P Global Corporate Sustainability Assessment

    2nd

Products and pipeline

  • Vaccines and medicines that are currently in development

    68
  • Number of phase I programmes started in 2022

    16
  • Number of assets in phase III/registration in 2022

    18
  • Major new vaccines and medicines approved since mid 2017

    >20
Vaccines
  • Vaccines in our portfolio

    20+
  • Vaccine doses delivered each day

    1.5m
  • Children receiving a GSK vaccine each year

    4 in 10
Specialty medicines
  • To pioneer HIV treatments in 1980 and leaders in ​HIV innovation

    1st
  • New medicine ​for Lupus in 50+ years

    1st
General medicines
  • Patients reached with our general medicines over the next ten years

    700m
  • Medicines in our portfolio

    150+
  • Helping millions of people with respiratory conditions to breathe more easily

    50 years